中文版
Home
About Us
Company Profile
Culture
Join Us
Contact Us
Products
Marketed Vaccine
R&D Vaccine
R&D
R&D Overview
Research achievements
International
International project
Overseas Market
International Certificate
News
Company News
Industry News
Latest Announcement
Home
About Us
Company Profile
About Us
Enterprise Honor
Development History
Culture
Cultural Concept
Staff Presence
Social Responsibility
Join Us
Join Us
Talent Concept
Well-paid Job
Contact Us
Products
Marketed Vaccine
SARS-COV-2 VACCINE(VERO CELL), INACTIVATED
Hib Conjugate Vaccine, Freeze-dried
13-Valent Pneumococcal Conjugate Vaccine
Recombinant Hepatitis B Vaccine
23-Valent Pneumococcal Polysaccharide Vaccine
Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine
Haemophilus Influenzae Type b Conjugate Vaccine
Measles and Rubella Combined Vaccine ,Live
R&D Vaccine
Rabies vaccine (human diploid cell) for human use, Freeze-dried
Inactivated Poliomyelitis Vaccine, Sabin Strains
Live attenuated Varicella Vaccine, Freeze-dried
Service
Vaccine Science
Information Disclosure
R&D
R&D Overview
Scientific Payoffs
R&D Project
International
Cooperative Project
International Exchange
International Certificate
GMP Certificate
Products Certificate
Overseas Market
Investor Relations
Corporate Governance
Company Announcements
Shareholder Returns
Stock quotation
Investor Online
Investors Contact
News
Company News
Industry News
Latest Announcement
中文版
Home
>
News
>
News
Company news
Industry news
Latest announcement
News
2022-08-31
Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.
2022-07-06
BioKangtai’s Shenzhen Guangming Base has passed the GMP certification in the Philippines
2022-05-08
BioKangtai passed the EU QP audit quality management system and reached the EU GMP standard
2022-02-24
Shenzhen starts offering Kangtai COVID booster shots
2022-02-21
BioKangtai's Inactivated COVID-19 Vaccine (Vero Cell) is Approved Homologous Booster Vaccination in China
2022-01-11
BioKangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Was Approved As Booster Dose in Indonesia
2021-12-30
BioKangtai 30 Million Doses of Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported
2021-11-19
Kangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported for the First Time
2021-11-18
China's BioKangtai Begins First Shipment of AstraZeneca's COVID-19 Shot
2021-11-03
BioKangtai's Adenovirus Vector COVID-19 Vaccine Obtained EUA in Indonesia
2021-09-06
Biokangtai:RecombinantCOVID-19 Vaccine(AdenovirusVector)licensed formanufacturing,whichactively promotesvaccineexportandimproves vaccineaccessibility
2021-08-04
Shenzhen Kangtai says vaccine effective against Delta variant
2021-08-02
BIOKANGTAI COVID-19 Vaccine Approved for Phase III Clinical Trial in the Philippines
2021-06-23
Phase III Clinical Trial of BIOKANGTAI COVID-19 Vaccine Initiated in Malaysia
2021-06-02
Indigenous COVID-19 vaccine put into use in city
2021-02-09
China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
2021-02-03
XINHUANET:China drugmaker begins trial production of AstraZeneca COVID-19 vaccine
2020-12-01
TYPES OF COVID-19 VACCINES
2020-12-01
COVID-19: A Basic Guide to Different Vaccine Types and How They Work
2020-12-01
With global push for COVID-19 vaccines, China aims to win friends and cut deals
2020-10-27
BioKangtai’ s COVID-19 Inactivated Vaccine Received Approval for Clinical Trial
0755-26988688